SCHEMBL5060258

SCHEMBL5060258

CNc1ncc2cc(-c3ccc(F)c(NC(=O)Nc4cn(C(C)C)nc4-c4ccccc4)c3)c(=O)n(C(C)C)c2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 8/20 0.42
RAF1 P04049 5/20 0.42
KRAS P01116 4/20 0.42
KDR P35968 4/20 0.42
MAP2K2 P36507 2/20 0.41
MAP2K1 Q02750 2/20 0.41
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
JAK2 O60674 1/20 0.36
KIT P10721 1/20 0.35
PDGFRA P16234 1/20 0.35
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CCND2 P30279 1/20 0.35
CCND3 P30281 1/20 0.35
MAPK8 P45983 2/20 0.35
NR1I2 O75469 1/20 0.35
CYP2C9 P11712 1/20 0.35
IDO1 P14902 1/20 0.35
GAK O14976 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5056538 0.95 BRAF (0.42) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5056310 0.93 BRAF (0.40) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5062245 0.93 BRAF (0.40) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5052141 0.92 BRAF (0.47) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5054582 0.91 BRAF (0.40) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5062463 0.91 BRAF (0.43) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5055034 0.90 BRAF (0.38) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5056511 0.90 RAF1 (0.51) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5055264 0.89 BRAF (0.39) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5067015 0.88 BRAF (0.46) BRAFRAF1KRASKDRMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 BRAF 2/4885RAF1 55/4885KRAS 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.